Health-related quality of life using the FACT-M questionnaire in patients with malignant melanoma: A systematic review

Bagge, Ann‐Sophie Lindqvist; Wesslau, Hanna; Cizek, Roza; Holmberg, Carl Jacob; Moncrieff, Marc; Katsarelias, Dimitrios; Carlander, Anders; Bagge, Roger Olofsson

doi:10.1016/j.ejso.2021.09.013

Cited by 4 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this systematic review and meta‐analysis of psychological and behavioral symptoms in patients with melanoma. One strength of our systematic review and meta‐analysis is that previously published reviews have primarily focused on depression, anxiety, and quality of life in patients with uveal melanoma 29–31 . The present review provides an overview of a broader range of psychological and behavioral symptoms that are part of a cancer symptom cluster, and provide a more nuanced picture of, primarily anxiety and depression, in both cutaneous and uveal melanoma patients before, during, and after completion of treatment.…”

Section: Discussionmentioning

confidence: 97%

“…One strength of our systematic review and meta-analysis is that previously published reviews have primarily focused on depression, anxiety, and quality of life in patients with uveal melanoma. [29][30][31] The present review provides an overview of a broader range of psychological and behavioral symptoms that are part of a cancer symptom cluster, and provide a more nuanced picture of, primarily anxiety and depression, in both cutaneous and uveal melanoma patients before, during, and after completion of treatment. The majority of studies investigated depression and anxiety, with pooled prevalence rates of depressive symptoms and anxiety ranging from 8% to 12% and 15%-19% respectively across time points (before, during, and after treatment).…”

Section: Discussionmentioning

confidence: 99%

“…27 A more recent systematic review of 18 studies showed that patients with uveal melanoma experienced impaired physical functioning and well-being after treatment. 28 Several studies included in these reviews have focused on psychological distress and quality of life in melanoma patients, 27,[29][30][31] but have typically not examined other symptoms that often co-occur in cancer patients. Indeed, in cancer patients, such symptoms may contribute to or even exacerbate each other over time 19,32 with important treatment implications.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Psychological and behavioral symptoms in patients with melanoma: A systematic review and meta‐analysis

et al. 2023

View full text Add to dashboard Cite

ObjectiveImproved survival rates have made it increasingly important for clinicians to focus on cancer survivorship issues affecting the quality of life of melanoma patients. To provide a comprehensive overview of the disease and treatment‐related issues affecting such patients, we conducted a systematic review and meta‐analysis of the literature to estimate the prevalence of symptoms of depression, anxiety, fatigue, sleep disturbance, and cognitive problems among melanoma patients, both uveal and cutaneous, before, during and after treatment.MethodsThe review was preregistered with PROSPERO (#CRD42020189847) and reported following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. A comprehensive search of the literature published up until June 2022 was undertaken using PubMed, PsycInfo, the Cochrane Library, and CINAHL. Two independent reviewers screened 1418 records and quality‐rated included studies. The reported prevalence rates of symptoms were pooled using a random‐effects model.ResultsSixty‐six studies including a total of 12,400 melanoma patients published between 1992 and 2022 were included. Pooled prevalence rates ranged from 6% to 16% for depression and 7%–30% for anxiety across diagnoses (uveal and cutaneous melanoma) and assessment time points. One third of the patients (35%) reported clinically significant fatigue, 20%–44% had cognitive complaints, while prevalence of sleep disturbance was not reported. Quality assessment indicated that 80% of the studies were of good quality.ConclusionA large body of research shows that depression and anxiety symptoms are prevalent in melanoma patients before, during and after treatment. However, research examining other symptoms known to affect quality of life, such as fatigue, sleep disturbances, and cognitive problems, is still needed.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psychological and behavioral symptoms in patients with melanoma: A systematic review and meta‐analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

Quality of Life Predictors in Patients With Melanoma: A Machine Learning Approach

et al. 2022

View full text Add to dashboard Cite

Health related quality of life (HRQoL) is an important recognized health outcome for cancer treatments, but also disease course with slower recovery and increased morbidity. These issues are of implication in melanoma, which maintains a risk of disease progression for many years after diagnosis. This study aimed to explore and weigh factors in the perception of the quality of life and possible relationships with demographic–clinical characteristics in people with melanoma via a machine learning approach. In this observational study, patients with melanoma, without metastatic disease, were recruited from January 2020 to December 2021 with a follow-up of at least one year. Demographic variables and clinics were collected, and the 12-Item Short-Form Health Survey (SF-12) was adopted as the physical and mental aspects of the Health-Related Quality of Life (HRQoL) measure. All the variables were processed in a random forest model to weigh at each node of each tree of this machine learning regression model, their actual weight in SF-12 score. We included 203 melanoma patients, mean aged 59.25 ± 15.1 years: 56 (27%) affecting the upper limbs and 147 (73%) affecting the trunk. The model of 142 patients with no missing value, generating 92 trees (MSE = 0.45, R2 of 0.78), reported that the lesion site was the most influencing variable on HRQoL based on the decrease in Gini impurity in variable weighing at each node intersection in forest generation. In this scenario, we built two distinct models for lesion sites and demonstrated that the variable that most influenced the quality of life in upper limb melanoma was lymphedema, while BMI was in the trunk. Given these results, random forest regressions could play a crucial role in the clinical and rehabilitation approach. The machine-learning model for detecting the HRQoL predictor in melanoma patients indicates that the experienced lymphedema and BMI may influence the HRQoL perception. This study suggests that the prevention and treatment of lymphedema and bodyweight reduction might improve the quality of life in melanoma.

show abstract

Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases

Wesslau

Carlander

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Few studies have investigated the health-related quality of life (HRQOL) in patients with melanoma in-transit metastases (ITM). The aim was to investigate the association between tumor burden and HRQOL, including disparities pertaining to sex and age, in treatment-naïve patients with ITM. Methods: Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire was used to assess HRQOL Pairwise comparisons using t-tests between clinical cutoffs are presented and multiple linear regression analysis showing the unique associations of gender, age, number of tumors, tumor size, presence of lymph node metastases, and tumor localization. Results: A total of 95 patients, 47% females and 53% males (median age 72 years) were included between 2012 and 2021. Women scored significantly lower on emotional well-being (p = 0.038) and lower on FACT-M (p = 0.058). Patients who had ≥10 tumors scored significantly lower on FACT-M (p = 0.015), emotional- and functional well-being (p = 0.04, p = 0.004, respectively), melanoma scale (p = 0.005), and FACT-G (p = 0.027). There was no significant difference in HRQOL depending on age, size of tumors, localization, or presence of lymph node metastases. Conclusion: For patients with melanoma ITMs, the female sex and higher tumor burden (i.e., number of tumors) were significantly correlated with lower HRQOL. However, these findings do not fully explain HRQOL for this patient population, and future research should consider the possibility that there are specific questions for patients with ITM where current instruments might fail to measure their discomfort to the full extent.

show abstract

Health-related quality of life using the FACT-M questionnaire in patients with malignant melanoma: A systematic review

Cited by 4 publications

References 52 publications

Psychological and behavioral symptoms in patients with melanoma: A systematic review and meta‐analysis

Psychological and behavioral symptoms in patients with melanoma: A systematic review and meta‐analysis

Quality of Life Predictors in Patients With Melanoma: A Machine Learning Approach

Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases

Contact Info

Product

Resources

About